UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

189 Establishment, Characterization and in Vivo Evaluation of Preclinical Tumor Models to Elucidate Differential Response to EGFR-targeted Therapies

European journal of cancer (1990), 2012-11, Vol.48, p.57-57

2012

Volltextzugriff (PDF)

Establishment and characterization of HPV+ metastatic squamous cell anal carcinoma XPDX models in athymic nude mice

European journal of cancer (1990), 2022-10, Vol.174, p.S13-S14

2022

Volltextzugriff (PDF)

Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies

European journal of cancer (1990), 2022-10, Vol.174, p.S14-S14

2022

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP

Journal of clinical oncology, 1998-09, Vol.16 (9), p.2964-2976

1998

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 1999-06, Vol.17 (6), p.1915-1925

1999

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors

Journal of clinical oncology, 1999-02, Vol.17 (2), p.685-696

1999

Volltextzugriff (PDF)

Identification and molecular characterization of invasive lobular breast cancer models in a panel of 180 breast XPDX models

European journal of cancer (1990), 2022-10, Vol.174, p.S121-S121

2022

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Cancer chemotherapy and pharmacology, 2009-05, Vol.63 (6), p.1073-1082

2009

Volltextzugriff (PDF)

Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel

Clinical cancer research, 2000-09, Vol.6 (9), p.3459-3468

2000

Volltextzugriff (PDF)

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy

Breast cancer research and treatment, 2006, Vol.95 (1), p.13-16

2006

Volltextzugriff (PDF)

284 Establishment and characterization of individualized patient-derived low passage human tumor models: Development, validation and evaluation for clinical correlation analysis

European journal of cancer supplements, 2010, Vol.8 (7), p.92-92

2010

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2000-01, Vol.18 (1), p.167-177

2000

Volltextzugriff (PDF)

Tesetaxel: Development of a weekly dosing schedule for an oral advanced-generation taxane

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13045-e13045

2011

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer

Journal of clinical oncology, 2000-12, Vol.18 (23), p.3974-3985

2000

Volltextzugriff (PDF)

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies

Annals of oncology, 2000-10, Vol.11 (10), p.1313-1322

2000

Volltextzugriff (PDF)

Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3074-3074

2011

Volltextzugriff (PDF)

A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema

Annals of oncology, 1998-01, Vol.9 (1), p.71-77

1998

Volltextzugriff (PDF)

Abstract P3-03-05: Establishment and evaluation of ER+ breast cancer models using an optimized methodology for exogenous hormone delivery

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-03-05

2016

Volltextzugriff (PDF)

Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.15523-15523

2008

Volltextzugriff (PDF)

SPARC and CA19–9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.15592-15592

2008

Volltextzugriff (PDF)

ER alpha genotypes and breast cancer recurrence

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.501-501

2008

Volltextzugriff (PDF)

New anticancer agents in clinical development

Oncology (Williston Park, N.Y.), 1995-11, Vol.9 (11), p.1191

1995

Volltextzugriff (PDF)

DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3151-3163

2000

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 1999-04, Vol.17 (4), p.1095-1104

1999

Volltextzugriff (PDF)

Alternative dosing schedules for irinotecan

Oncology (Williston Park, N.Y.), 1998-08, Vol.12 (8 Suppl 6), p.68

1998

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Humans
(28)
Female
(24)
Oncology
(24)
Biological And Medical Sciences
(22)
Middle Aged
(22)
Medical Sciences
(20)
Adult
(19)
Male
(19)
Aged
(18)
Antineoplastic Agents
(15)
Chemotherapy
(15)
Pharmacology. Drug Treatments
(15)
Neoplasms - Drug Therapy
(14)
Dose-Response Relationship, Drug
(13)
Neoplasms - Metabolism
(9)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Aged, 80 And Over
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

189 Establishment, Characterization and in Vivo Evaluation of Preclinical Tumor Models to Elucidate Differential Response to EGFR-targeted Therapies

Establishment and characterization of HPV+ metastatic squamous cell anal carcinoma XPDX models in athymic nude mice

Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors

Identification and molecular characterization of invasive lobular breast cancer models in a panel of 180 breast XPDX models

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy

284 Establishment and characterization of individualized patient-derived low passage human tumor models: Development, validation and evaluation for clinical correlation analysis

Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies

Tesetaxel: Development of a weekly dosing schedule for an oral advanced-generation taxane

Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies

Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens

A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema

Abstract P3-03-05: Establishment and evaluation of ER+ breast cancer models using an optimized methodology for exogenous hormone delivery

Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer

SPARC and CA19–9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine

ER alpha genotypes and breast cancer recurrence

New anticancer agents in clinical development

DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

Alternative dosing schedules for irinotecan

Suchergebnisse filtern